Reinvention is everywhere. Products get updated, industries change course, and ideas we once treated as finished suddenly come back in a new form. Something that felt permanent five years ago can look completely different today, redesigned for a new audience or a new moment.
Ever more drug developers are searching for CDMOs with contamination-limiting capabilities. But how can they know which have these high-potency credentials?
Achieving global approval for a single change may take three to five years, but inefficient lifecycle change management rarely registers as a crisis.
Major issues in clinical oversight are latency and heterogeneity across systems including formats, identifiers, coding conventions, and timing of updates.
Simtra’s capability to support high-volume injectables and lower-volume modalities provides balanced expertise across the sterile injectables landscape.
With the increasing complexities of current IND programs, it is critical to work with regulatory agencies to seek input early in the process.
Holding individuals and teams explicitly accountable for data accuracy and quality might seem straightforward, but it is difficult to sustain in practice.
Deploying AI agents to handle data collection, coding, medical review, and quality-checking makes signal management autonomous at the processing stage.
In agentic AI-enabled labs, AI goes from individual, one-off applications to comprehensive workflow orchestration.
CROs supporting early-stage drug discovery projects are establishing their own internal AI platforms to address their clients’ needs in an evolving field.
The NDAs approved during the first quarter of 2026 have been divided into the dosage forms Injection, Tablets, Capsules, Oral solution, Gas, and other.